Atripla

Type: Product
Name: Atripla
First reported 2 hours ago - Updated 2 hours ago - 1 reports

Taking Your First HIV Med With the Encouragement of a Loved One

I lost my partner to AIDS in 1994. I was still negative. I volunteered for AIDS organizations and lost so many friends. I saw all the experimental medications come and the toll it took on all their lives. So the day I was diagnosed as positive I just ... [Published The Body - 2 hours ago]
First reported Apr 23 2014 - Updated Apr 23 2014 - 3 reports

Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales - Analyst Blog

Gilead Sciences, Inc. (NASDAQ: GILD) made a strong start to 2014, with both revenues as well as earnings beating expectations by huge margins in the first quarter of the year. The company's first-quarter 2014 earnings (including stock-based compensation ... [Published Benzinga.com - Apr 23 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

I serve everyone, heterosexual or gay

By Asunta WaguraMore byJON* Had been calling me persistently. Actually, I was almost moving his phone number to the sumbua group when I finally decided to accept his call and get to the bottom of whatever was bothering him, once and for all.“My life is ... [Published Daily Nation - Apr 23 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Gilead Crushes On Earnings, Quickly Gives Up Gains

Benzinga - 48 mins agoShares of Gilead Sciences (NASDAQ: GILD) traded up sharply before turning back, remaining up 1.18 percent to $72.86 in Tuesday's post market session after blowing away analysts' first quarter estimates.The company reported earnings ... [Published Yahoo! Finance - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Gilead Sciences Drops Jaws With a 209% Increase in Q1 Net Income

Infectious disease-focused biopharmaceutical company Gilead Sciences ( NASDAQ: GILD     ) did nothing short of dazzle Wall Street after the closing bell by reporting impressive top- and bottom-line growth in the first quarter .Total revenue for the quarter ... [Published Motley Fool Discussion Boards - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Global HIV Therapeutics in Major Developed Markets to 2019

Research and Markets (http://www.researchandmarkets.com/research/n2xgls/hiv_therapeutics) has announced the addition of the "HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent ... [Published Individual.com - Apr 22 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

HIV market growth to be impacted by patent expiries

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a compound annual growth rate (CAGR) ... [Published Pharma Letter - Apr 16 2014]
Entities: HIV/AIDS, Tenofovir, Patent
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

A frustrated letter to my trusted doctor

Dear Dr Kinyanjui,It is now 32 days since you put me on the wonder drug, Atripla.I feel that I need to give you an update on how I am fairing. I am headed to your office to drop the remaining drugs and to let you know that I am done with them.To start ... [Published Daily Nation - Apr 09 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Study Looks at Earliest Health Law Enrollees

c.2014 New York Times News ServicePeople who signed up early for insurance through the new marketplaces were more likely to be prescribed drugs to treat pain, depression and HIV and were less likely to need contraceptives, according to a new study that ... [Published Columbus - Apr 09 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Antiretroviral Therapy in 2014: How Does a Doctor Choose?

While development of drugs for HIV infection has definitely slowed over the last several years, treatment options continue to expand and improve, making antiretroviral therapy (ART) easier, better tolerated, and more convenient. In this article, I'll ... [Published The Body - Apr 05 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Starting Antiretrovirals Wasn't an Option

Aaron LaxtonStarting on ARVs [antiretrovirals] wasn't an option. From all the research I had done, I knew that the quicker that I started medications, the better chance I would have to remain healthy. I was diagnosed on June 6, 2011, and almost a month ... [Published The Body - Apr 02 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Atripla, Vivid Dreams and Getting Past the Undetectable Brick Wall

Part of the Series Other Sides of HIV : People Taking HIV Meds Share Stories About Side EffectsMikeAfter being told I was HIV positive, for me it was a no-brainer. I started medications right away; when I say right away, it was more like three months, ... [Published The Body - Apr 01 2014]

Quotes

Research and Markets (http://www.researchandmarkets.com/research/n2xgls/hiv_therapeutics) has announced the addition of the "HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth" report to their offering...
"People with H I V were basically frozen out of the private insurance market up until now" Mr. Schmid said
...(KHN is an editorially independent program of the foundation.) "There are clearly some people with expensive conditions enrolled, but it's not clear yet what proportion they represent."
..."The side effects are a bitch!" he says jokingly but serious at the same time. "I felt as though I had the pneumonia all over again. I was weak and couldn't walk, was like the flu x10." He also experienced a lot of the other common symptoms of Atripla such as the dizziness and his vivid dreams...

More Content

All (50) | News (46) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Taking Your First HIV Med With the Encouragemen... [Published The Body - 2 hours ago]
Earnings from Gilead and Amgen Put These ETFs i... [Published Yahoo! Finance - Apr 23 2014]
Strong Q1 Earnings at Gilead on Stellar Sovaldi... [Published Benzinga.com - Apr 23 2014]
Strong Q1 Earnings at Gilead on Stellar Sovaldi... [Published Yahoo! Finance - Apr 23 2014]
I serve everyone, heterosexual or gay [Published Daily Nation - Apr 23 2014]
Gilead Sciences' CEO Discusses Q1 2014 Results ... [Published Seeking Alpha - Apr 23 2014]
Gilead Sciences Q1 Profit More Than Triples, Re... [Published RTTNews.com - Apr 23 2014]
Gilead Crushes On Earnings, Quickly Gives Up Gains [Published Yahoo! Finance - Apr 22 2014]
Gilead Sciences Drops Jaws With a 209% Increase... [Published Motley Fool Discussion Boards - Apr 22 2014]
Global HIV Therapeutics in Major Developed Mark... [Published Individual.com - Apr 22 2014]
Market Update (NASDAQ:GILD): Gilead Sciences’ N... [Published Jutia Group - Apr 21 2014]
Stock Update: Gilead Sciences Inc (NASDAQ:GILD)... [Published Jutia Group - Apr 17 2014]
If This Biotech Drops Much Further I'm Going to... [Published Motley Fool Discussion Boards - Apr 17 2014]
HIV market growth to be impacted by patent expi... [Published Pharma Letter - Apr 16 2014]
Predicting kidney problems [Published Aidsmap - Apr 15 2014]
Company Update (NASDAQ:GILD): Texas Medicaid ho... [Published Jutia Group - Apr 11 2014]
Study: Obamacare enrollees older, sicker and mo... [Published U-T San Diego - Apr 11 2014]
National Sales Manager [Published PharmaDiversity - Apr 11 2014]
Early ACA enrollees more likely to be sicker, s... [Published Medical Economics - Apr 11 2014]
Five Star Stock Watch: Gilead Sciences [Published Benzinga.com - Apr 10 2014]
Starting HIV Treatment Amidst Anger and Depression [Published The Body - Apr 10 2014]
A frustrated letter to my trusted doctor [Published Daily Nation - Apr 09 2014]
Sicklier patients enroll in Obamacare, study finds [Published CNBC - Apr 09 2014]
Early Drug Claims Suggest Exchange Plan Enrolle... [Published Kaiser Health News - Apr 09 2014]
Study Looks at Earliest Health Law Enrollees [Published Columbus - Apr 09 2014]
24-Year-Old Former Porn Model Given an AIDS Dia... [Published The Body - Apr 08 2014]
Antiretroviral Therapy in 2014: How Does a Doct... [Published The Body - Apr 05 2014]
CROI 2014: Researchers Discuss HIV, Aging, and ... [Published HIV and Hepatitis.com - Apr 04 2014]
Starting Antiretrovirals Wasn't an Option [Published The Body - Apr 02 2014]
Gilead/J&J NDA Could Mean Another Fixed-Dose Re... [Published Health News Daily - Apr 02 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Gilead Sciences: What Happened Today? [Published BARRONS.com Stocks To Watch Today - Mar 07 2014]
Shares of Gilead Sciences (GILD) fell 3.6% today, and the experts I spoke with said that they didn’t see a catalyst for the drop, one that dragged the entire biotech sector down with it. Now there are two possibilities. StreetInsider.com and the Fly On ...
Anyone Could Spare Me On Atripla? [Published HealthBoards - Feb 03 2014]
Hi, I was wondering if anyone could spare maybe 2 or 3 Atripla tablets? (I live in Baton Rouge). I requested a Refill from my pharmacy and was told that they were unable to refill my prescription because it's showing that I am no longer covered. I filled ...
Drug Patent Expirations for November 21 2013 [Published Biotech Blog - Nov 22 2013]
Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ...
Drug Patent Expirations in November 2013 [Published Biotech Blog - Nov 11 2013]
Copyright © thinkBiotech Drug Patent Expirations for November 2013TradenameApplicantGeneric NamePatent NumberPatent Expiration SAMSCA Otsuka America Pharm tolvaptan 5,258,510 Nov 2, 2013 PROPECIA Merck finasteride 5,571,817 Nov 5, 2013 ACIPHEX ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.